On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri, will be widely used to screen for cancer, will become a publicly traded stock (with the ticker GRAL) that any investor can buy or sell on the Nasdaq.
That will, in a sense, end a long, strange trip that has taken a decade. Grail was spun out by the DNA sequencing giant Illumina in 2015. In 2020, Illumina announced plans to purchase the company for $8 billion. But that deal, though eventually closed, was scuttled by regulatory issues in both the U.S. and Europe, and European regulators forced Illumina to spin Grail back out.
Grail now says it expects to file for full approval in the U.S. in 2026. In the meantime, the company is running an annual loss of about $500 million a year. As part of the agreement to spin it out, Illumina has capitalized it with about 2 1/2 years worth of funding.
Click this link for the original source of this article.
Author: Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.